Evaluation of SPN-812 ER High Dose in Adolescents With ADHD

Trial Profile

Evaluation of SPN-812 ER High Dose in Adolescents With ADHD

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 Status changed from planning to not yet recruiting.
    • 10 Mar 2017 New trial record
    • 28 Feb 2017 According to a Supernus Pharmaceuticals media release, company will initiate this phase III clinical testing during the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top